Compounds > l 733060
Page last updated: 2024-09-03

l 733060 and cp 96345

l 733060 has been researched along with cp 96345 in 5 studies

Compound Research Comparison

Studies
(l 733060)		Trials
(l 733060)		Recent Studies (post-2010)
(l 733060)		Studies
(cp 96345)		Trials
(cp 96345)		Recent Studies (post-2010) (cp 96345)
71032403116

Protein Interaction Comparison

ProteinTaxonomyl 733060 (IC50)cp 96345 (IC50)
Substance-P receptorHomo sapiens (human)0.0028
Substance-P receptorCavia porcellus (domestic guinea pig)0.0004

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cascieri, MA; Hale, JJ; MacCoss, M; MacIntyre, DE; Mathre, DJ; Metzger, JM; Mills, SG; Qi, H; Sadowski, S; Shah, SK; Strader, CD1
Beusen, DD; Marshall, GR; Shands, EF; Takeuchi, Y1
Alvaro, G; Braggio, S; Carletti, R; Corsi, M; Di Fabio, R; Gerrard, PA; Griffante, C; Marchioro, C; Melotto, S; Piccoli, L; Poffe, A; Pozzan, A; Ratti, E; Spada, S; Tranquillini, E; Trower, M1
Bang, R; Kiemer, AK; Neuhuber, WL; Sass, G; Tiegs, G; Vollmar, AM1
Alevizos, M; Conti, P; Karagkouni, A; Leeman, SE; Norwitz, E; Taracanova, A; Theoharides, TC; Weng, Z1

Other Studies

5 other study(ies) available for l 733060 and cp 96345

ArticleYear
2(S)-((3,5-bis(trifluoromethyl)benzyl)-oxy)-3(S)-phenyl-4- ((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine (1): a potent, orally active, morpholine-based human neurokinin-1 receptor antagonist.
    Journal of medicinal chemistry, 1996, Apr-26, Volume: 39, Issue:9

    Topics: Administration, Oral; Animals; CHO Cells; Cricetinae; Humans; Morpholines; Neurokinin-1 Receptor Antagonists

1996
Derivation of a three-dimensional pharmacophore model of substance P antagonists bound to the neurokinin-1 receptor.
    Journal of medicinal chemistry, 1998, Sep-10, Volume: 41, Issue:19

    Topics: Binding Sites; Biphenyl Compounds; Crystallography, X-Ray; Ligands; Models, Molecular; Molecular Conformation; Neurokinin-1 Receptor Antagonists; Receptors, Neurokinin-1; Structure-Activity Relationship; Substance P

1998
Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
    Bioorganic & medicinal chemistry, 2013, Nov-01, Volume: 21, Issue:21

    Topics: Animals; Antidepressive Agents; Behavior, Animal; Bridged Bicyclo Compounds, Heterocyclic; CHO Cells; Cricetinae; Cricetulus; Dogs; Female; Gerbillinae; Half-Life; Humans; Male; Models, Molecular; Molecular Conformation; Neurokinin-1 Receptor Antagonists; Piperazines; Piperidines; Protein Binding; Rats; Receptors, Neurokinin-1

2013
Neurokinin-1 receptor antagonists CP-96,345 and L-733,060 protect mice from cytokine-mediated liver injury.
    The Journal of pharmacology and experimental therapeutics, 2003, Volume: 305, Issue:1

    Topics: Animals; Base Sequence; Biphenyl Compounds; Capsaicin; Chemical and Drug Induced Liver Injury; Cytokines; Dose-Response Relationship, Drug; Gene Expression; Lipopolysaccharides; Liver Diseases; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Neurokinin-1 Receptor Antagonists; Neurons, Afferent; Piperidines; RNA, Messenger; Sequence Homology, Nucleic Acid; Time Factors; Transcriptional Activation

2003
SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors.
    Proceedings of the National Academy of Sciences of the United States of America, 2017, 05-16, Volume: 114, Issue:20

    Topics: Biphenyl Compounds; Cell Line, Tumor; Humans; Interleukin-1 Receptor-Like 1 Protein; Interleukin-33; Luteolin; MAP Kinase Signaling System; Mast Cells; NF-kappa B; Piperidines; Receptors, Neurokinin-1; Substance P; Tumor Necrosis Factor-alpha

2017